GLP-1 Drugs Surge as Obesity Treatment, Surgery Rates Decline

A recent study observed a **132.6% rise** in the use of GLP-1 drugs for obesity treatment from 2022 to 2023, while **bariatric surgery dropped by 25.6%**. Only 6% of patients received either treatment, signaling room for increased treatment access. Despite GLP-1's popularity, surgery remains the most effective long-term solution.